1,3-Dimethyl-1-propylurea | 76802-52-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1,3-Dimethyl-1-propylurea
• CAS: 76802-52-3
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: RNHVJBJVOGMYMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3-Dimethyl-1-propylurea 、 异氰酸苯酯 在 四氯化锡 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以40%的产率得到1,3-Dimethyl-1-n-propyl-5-phenylbiuret
  参考文献：
  名称：

  芳基缩二脲的合成、抗炎和镇痛活性

  摘要：

  通过使用角叉菜胶爪水肿和乙酸拉伸试验，制备并评估了许多芳基缩二脲作为抗炎和镇痛剂。其中，1,3-二甲基-5-苯基缩二脲（7）、l-乙基-3-甲基-5-苯基缩二脲（11）、1,1,3-三甲基-5-苯基缩二脲（11）的抗炎活性（ 13) 被发现比保泰松更有效。7和5-(4-氯苯基)-1,13-三甲基苯基缩二脲(16)的镇痛活性高于氨基比林。

  DOI：

  10.1002/ardp.19903230607

文献信息

• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009067613A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物，式(I)。其中R1、R2、R3、R4和L1在规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物，式(II)。其中R1a、R2a、Rx和n如规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• THIAZOLYL-DIHYDRO-QUINAZOLINE
  申请人：Brandl Trixi

  公开号：US20070244104A1

  公开（公告）日：2007-10-18

  Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R 1 to R 4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

  揭示了一般式（I）的噻唑基-二氢喹唑啉化合物，其中基团R1至R4具有权利要求和说明书中给定的含义，其异构体，以及制备这些化合物的过程以及它们作为药物组成物的用途。
• DIAZENIUMDIOLATE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
  申请人：Cordi Alexis

  公开号：US20100286225A1

  公开（公告）日：2010-11-11

  Compounds of formula (I): wherein: R 1 represents a hydrogen atom or a —COOR group, R 2 represents a group G or a linear or branched (C 1 -C 6 )alkyl group substituted by a group G, wherein G represents a —(CH 2 ) n -A-(CH 2 ) m —B—(CR 4 R 5 ) p —(CH 2 ) o -R 6 group as defined in the description, R 3 represents a hydrogen atom, an alkyl group or an NO 2 group.

  公式(I)的化合物： 其中： R1代表一个氢原子或一个—COOR基团， R2代表一个G组或一个被G组取代的线性或支链的(C1-C6)烷基团，其中G代表如说明中定义的—(CH2)n-A-(CH2)m—B—(CR4R5)p—(CH2)o-R6基团， R3代表一个氢原子、一个烷基团或一个NO2基团。
• Novel Sirtuin Activating Compounds and Methods for Making the Same
  申请人：Andrus Merritt B.

  公开号：US20080255382A1

  公开（公告）日：2008-10-16

  The present invention includes methods for preparing resveratrol, resveratrol esters and substituted and unsubstituted stilbenes of the formula given below; where each Y is —O or halogen, each Z is —O or halogen, each n and each m is independently the value of 0, 1, 2, 3, 4 or 5, each A and each B is independently selected from P n , R or absent, each V and each W is independently selected from P n , straight or branched alkyl of from (2) to (6) carbon atoms and cycloalkyl of from (3) to (8) carbon atoms, alkoxy, phenyl, benzyl or halogen, R is independently selected from the group comprising alkyl with at least one carbon atom, aryl and aralkyl, P n is an alcohol protecting group and diastereoisomers of the foregoing. The compounds are made from a multi-step process including a N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners. These compounds show increased stability for use in the food, cosmetic and pharmaceutical industries.

  本发明涉及一种制备白藜芦醇、白藜芦醇酯和给定以下结构式的取代和未取代的stilbenes的方法；其中每个Y是—O或卤素，每个Z是—O或卤素，每个n和每个m独立地取值为0、1、2、3、4或5，每个A和每个B独立地从Pn、R或缺席中选择，每个V和每个W独立地从Pn、由（2）到（6）个碳原子的直链或支链烷基和由（3）到（8）个碳原子的环烷基、烷氧基、苯基、苄基或卤素中选择，R独立地从包括至少一个碳原子的烷基、芳基和芳基烷基的群体中选择，Pn是醇保护基和上述化合物的对映异构体。这些化合物是通过多步过程制备的，其中包括在碱存在下与苄基卤和苯乙烯偶联合成N-杂环碳型配体偶联。这些化合物在食品、化妆品和制药行业中显示出增强的稳定性。
• Novel 1,1,3,5-substituted biuret compound and a pharmaceutical
  申请人：Taiho Pharmaceutical Company Limited

  公开号：US04293713A1

  公开（公告）日：1981-10-06

  A novel 1,1,3,5-substituted biuret compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are respectively the same or different, and each are alkyl groups having 1 to 4 carbon atoms; R.sup.3 is a cyclohexyl group or a phenyl group which may be unsubstituted or may have at least one substituent selected from the group consisting of chlorine, bromine, fluorine, methyl, trifluoromethyl, dimethylamino, methoxy, methylthio, nitro and acetyl. The novel 1,1,3,5-substituted biuret compounds are useful as an analgesic, anti-inflammatory and/or anti-pyretic agent.

  一种新颖的1,1,3,5-取代的双脲化合物，化学式如下：##STR1##其中R.sup.1和R.sup.2分别相同或不同，且均为含有1至4个碳原子的烷基基团；R.sup.3为环己基基团或苯基基团，可以是未取代的，也可以具有至少一种来自氯、溴、氟、甲基、三氟甲基、二甲胺基、甲氧基、甲硫基、硝基和乙酰基的取代基。这种新颖的1,1,3,5-取代的双脲化合物可用作镇痛剂、抗炎和/或退热剂。